focus -WSS

focus

author：comprehensive 2025-08-12 09:09:22 - browse：8244

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： SCOTUS to consider access to abortion pill mifepristone

focus

knowledge

WSS

Teach medical students about patients with intellectual disabilities

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Will the market for weight loss drugs really reach $100 billion?

CMS should re

AI models in health care face new federal disclosure requirements

After sickle

entertainment

focus

explore

Affirmative action in medical school literally saved lives

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Malaria cases in Florida and Texas: Here’s what you need to know

The woman behind the Dana Farber

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AI models in health care face new federal disclosure requirements

Cancer drug shortages should be causing more outrage

CMS should re

Apple is now the first public company to be valued at $3 trillion

Cigna, Humana reportedly in talks to merge

knowledge

FDA needs staff influx to meet gene therapy needs, Marks says

UnitedHealth’s Optum accused of antitrust violations in California

Diagnostic tests are hitting their mathematical limits

Flagship Pioneering launches a new biotech in two countries

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Roche to buy Carmot Therapeutics, developer of obesity drugs

focus

hotspot

knowledge

leisure time